Skip to content

Price / earnings at other companies

Royalty Pharma logo
Royalty PharmaRPRX
24.8×+12.5×
Revvity logo
RevvityRVTY
40.9×-3.5×
Roivant Sciences logo
Roivant SciencesROIV
249.7×+248×
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
50.4×
ALN
Alnylam PharmaceuticalsALNY
87.4×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
17×-6.2×

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's price / earnings?
Ligand Pharmaceuticals (LGND) reported price / earnings of 25.9× in Q1 2026.
What is the long-term trend for Ligand Pharmaceuticals's price / earnings?
Over 2 years (2021 to 2025), Ligand Pharmaceuticals's price / earnings has grown at a -18.6% compound annual growth rate (CAGR), from 45.2× to 29.9×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.